NEW YORK, July 6, 2015 /PRNewswire/ --
INTRODUCTION
In today's pharmaceutical market, many drugs are supplied in
powdered formulation because of their lower shelf life in liquid
formulation. The drugs are formulated into powdered form by various
processes such as lyophilisation or spray drying; these drugs are
then reformulated into liquid form by mixing with a suitable
diluent at the time of administration. The overall market of drug
reconstitution systems is characterised by the presence of around
50 devices (both conventional and novel). The primary goal of these
systems is to provide a hassle free reconstitution process in
minimal number of steps. In addition, these systems also aim to
provide an optimal protection from needlestick injuries to both the
patients and healthcare providers.
Conventional drug reconstitution systems, including Vial Adaptors,
Vial to Vial Systems, Direct Connection to Vial Systems and a few
others, currently dominate the market. Some of these systems were
developed nearly two decades ago and have gained a significant
share of the market overtime. In addition, the use of traditional
hypodermic needles for reconstituting the drug using a diluent vial
is still widespread, especially in the developing countries.
However, with new needlestick injuries prevention laws being
implemented, along with rising approvals for biologic drugs, novel
reconstitution systems such as Dual Chamber Systems are expected to
be more popular and preferred option. A number of these novel
systems make the process as easy as the push of a button in a much
more safer and accurate manner.
Though the market for such novel devices is currently at nascent
stage, there are several devices available for investigational use.
The technology used in novel systems is likely to play an important
part in enhancing the safety, patient compliance and ease of use.
When ready, these devices are likely to have a significant impact
on the overall market landscape.
SCOPE OF THE REPORT
The 'Novel Drug Reconstitution Systems, 2014-2024 Market' report
provides a comprehensive study of the growing market of drug
reconstitution systems. As mentioned earlier, this includes not
only the conventional systems such as Vial Adaptors, Vial to Vial
Systems but also novel systems such as Dual Chamber Systems. Due to
an increasing number of biologics and the growing trend towards
self-administration of drugs, novel drug reconstitution devices are
becoming a key focus area for medical device manufacturers. The
focus of this study is primarily to understand the governing trends
and the likely future evolution of these devices over the next
decade.
The report covers various aspects such as market developments,
recent partnerships and our opinion on the likely drivers which
will influence the industry's evolution. In addition, we have
provided a holistic view of the market landscape including detailed
profiles of leading devices, key features and their comparative
position vis-à-vis other devices. Innovations in design and
advanced safety mechanisms will continue to present encouraging
prospects to device manufacturers in the years ahead.
In addition to the key benefits and the likely market drivers, this
study also highlights some of the challenges associated with the
use and implementation of these devices. Regular modifications in
design and incorporation of safety features present operational
challenges to the manufacturers. Cost is another factor that can
significantly restrain the market, especially in the case of novel
reconstitution systems. However, with the entrance of more devices
in the market, prices are expected to come down; this, in turn,
will result in a higher uptake of such systems.
The report also includes a special case study on drugs and vaccines
requiring reconstitution prior to administration. We have looked at
the specific indications, therapeutic areas and mode of
administration of these powdered formulations.
The study provides short-midterm and long term market forecasts for
the period 2014 - 2019 and 2019 - 2024, respectively. The research,
analysis and insights presented in this report are backed by a deep
understanding of key insights gathered from both secondary and
primary research.
EXAMPLE HIGHLIGHTS
1. We expect that the overall market for drug reconstitution
systems is likely to grow at an annualised rate of 7.3% over the
coming decade. Novel reconstitution systems will continue to gain
ground; by 2024, we expect them to contribute a significant share
(27%) to the overall market.
2. Increased venture capital interest is expected to drive
additional resources to fund future development. Other drivers
include the growing presence of lyophilised drugs, focus on
self-administration, convenient disposal, applicability to mass
immunisation / vaccination programmes and customisation options as
per end-user requirements.
3. Specific pockets of growth include 'closed systems', which are
expected to rise significantly as more number of chemotherapeutics
receive approval in the near future.
4. The market is characterised by the presence of various
established players such as West Pharmaceutical Services, Becton
Dickinsonalong with emerging firms such as Unilife Corporation,
Sensile Medical, Integrity Bio, Mystic Pharmaceuticals. Emergence
of small companies is expected to foster ongoing innovation in the
area.
5. The increasing number of partnerships is evident of the fact
that the leading companies actively look up to these smaller
companies for licensing the technology and use their own global
presence to make the technology widely available.
RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered via
secondary research. For all our projects, we conduct interviews
with experts in the area (academia, industry, medical practice and
other associations) to solicit their opinions on emerging trends in
the market. This is primarily useful for us to draw out our own
opinion on how the market will evolve across different regions and
technology segments. Where possible, the available data has been
checked for accuracy from multiple sources of information.
The secondary sources of information include
- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Industry analysts' views
While the focus has been on forecasting the market over the coming
ten years, the report also provides our independent view on various
technological and non-commercial trends emerging in the industry.
This opinion is solely based on our knowledge, research and
understanding of the relevant market gathered from various
secondary and primary sources of information.
CHAPTER OUTLINES
Chapter 2 provides an executive summary of major highlights
captured in the report. It offers a high level view on the likely
future of drug reconstitution systems market.
Chapter 3 provides a general introduction to the drug
reconstitution process. It covers the advantages of advanced
reconstitution systems over conventional systems including likely
benefits to both the patients and the manufacturers.
Chapter 4 provides a comprehensive analysis of the current market
of drug reconstitution systems. It lists 50 devices that can be
used to carry out reconstitution of powdered drugs, categorising
them into the various sub-types (Vial Adaptors, Vial to Vial
Systems, Direct Connection to Vial Systems, Dual Chamber Systems,
Closed Systems and Needle Free Systems), mode of delivery and the
nature of the device (disposable / reusable).
Chapter 5 provides detailed analysis on Dual Chamber Systems that
are used for reconstitution of lyophilised drugs. We have presented
a 2 X 2 matrix to compare the product competitiveness and supplier
power of several devices belonging to this category. The chapter
also provides detailed profiles of a number of Dual Chamber Systems
which are currently available either commercially or for
investigational use.
Chapter 6 focuses on other novel drug reconstitution systems. As in
the last chapter, we have provided detailed profiles and
highlighted key features of some of the upcoming devices in this
category.
Chapter 7 focuses on Needle Free Reconstitution Systems. Most of
these systems are used for infusion purposes. In addition to the
detailed profiles of such systems, we have also included a special
case study on ZetaJetTM, an advanced spring powered system that is
designed to deliver vaccines and injectable medication either
subcutaneously or intramuscularly.
Chapter 8 focuses on 24 conventional reconstitution systems which
were identified during the course of this study. For these Vial
Adaptors, Direct Connection to Vial Systems and Closed Systems, we
have done a 2 X 2 matrix to compare the product competitiveness
with respective supplier power. As in the earlier chapters, we have
also profiled a number of these devices.
Chapter 9 highlights the likely future evolution of drug
reconstitution systems market over the next ten years. We have done
separate analysis for both conventional and novel reconstitution
systems till the year 2024.
Chapter 10 provides information on FDA approved drugs and vaccines
which are supplied in powdered formulation. We have analysed the
product landscape highlighting the popular therapeutic areas and
the mode of drug administration.
Chapter 11 includes the detailed profiles of some of the major
players in the drug reconstitution systems market. For each
company, we have covered details on financial performance, product
portfolio, recent developments and future growth plans.
Chapter 12 captures the recent developments which have influenced
the drug reconstitution systems market. It includes the agreements
/ partnerships that have been inked between different stakeholders.
We have also provided a technology evolution roadmap clearly
depicting the key milestones which have shaped the industry thus
far.
Chapter 13 provides the SWOT analysis of drug reconstitution
systems market giving strategic insights to the major factors that
have contributed to the growth of this market. It also highlights
the weaknesses and threats that can negatively impact the
growth.
Chapter 14 is a collection of interview transcripts; for the
purposes of this study, we held discussions with several experts to
ascertain the key strategic initiatives and future roadmap of the
industry.
Chapter 15 summarises the overall report. In this chapter, we
provide a recap of the key takeaways and our independent opinion
based on the research and analysis described in previous
chapters.
Chapter 16 is an appendix, which provides tabulated data and
numbers for all the figures presented in the report.
Chapter 17 is an appendix, which provides a list of companies and
organisations mentioned in this report.
Read the full report:
http://www.reportlinker.com/p02530817-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution that
finds, filters and organizes the latest industry data so you get
all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/novel-drug-reconstitution-systems-market-2014---2024-300109136.html
SOURCE Reportlinker